Nico Gagelmann Shares Article on How Remission Conversion Drives Outcomes After CAR T-cell Therapy for Multiple Myeloma
Nico Gagelmann, Young National Society Ambassador at European Hematology Association (EHA) and Chair of the CAR-T for plasma cell disorder committee at The EBMT, shared a post on X:
“Finally out
Remission conversion drives outcomes after CAR T-cell therapy for multiple myeloma
Now in Blood Journals Portfolio
Timely for EHA2025″
Title: Remission conversion drives outcomes after CAR T-cell therapy for multiple myeloma: a registry analysis from the DRST
Authors: Maximilian Merz, Nico Gagelmann, Samih Smaili, Sarah Flossdorf, Sandra Sauer, Christof Scheid, Bastian von Tresckow, Gerald Georg Wulf, Katja C Weisel, Igor Blau, Monika Engelhardt, Ralph Wäsch, Natalie Schub, Raphael Teipel, Judith S. Hecker, Johannes M. Waldschmidt, Britta Besemer, Ben-Niklas Baermann, Simon Call, Leo Hansmann, Francis Ayuketang Ayuk, Marc S. Raab, Hermann Einsele, Uwe Platzbecker, Nicolaus Kröger
You can read the Full Article on Blood Journals Portfolio
More posts featuring Nico Gagelmann.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023